Project/Area Number |
15K09580
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Infectious disease medicine
|
Research Institution | Keio University |
Principal Investigator |
ISHII Makoto 慶應義塾大学, 医学部(信濃町), 講師 (30317333)
|
Co-Investigator(Renkei-kenkyūsha) |
NAKAYAMA Toshinori 千葉大学, 医学部免疫発生学教室, 教授 (50237468)
|
Research Collaborator |
YAGI Kazuma
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 重症感染症 / エピジェネティクス / インフルエンザ / 肺炎球菌 / ヒストンアセチル化 / 肺炎球菌性肺炎 / ヒストンメチル化 / Ezh2 / HDAC阻害薬 / 肺炎球菌感染 |
Outline of Final Research Achievements |
The hypothesis of the study was epigenetic mechanism, especially for histone acetylation, might contribute to the poor outcome of post-influenza pneumonia. Mice were infected intranasally with 1.0 × 104 CFU of Streptococcus pneumoniae 7 days after intranasal inoculation with 5 PFU of influenza virus A/PR8.The mice were intraperitoneally injected with the histone deacetylase (HDAC) inhibitor TSA. TSA significantly suppressed HDAC activity and significantly improved the survival rate of mice after post-influenza pneumococcal infection, which was associated with a significant decrease in bacterial load and the total cell count of the BALF. The number of natural killer cells in the lungs were significantly lower in the TSA-treated group, which may contribute to the protective effects of TSA. TSA protects mice against post-influenza pneumococcal pneumonia possibly through multiple factors, including a decrease in lung and systemic bacterial load, and suppression of systemic inflammation.
|